Where the Next Medical Innovation Deal Will Happen: Highlights Preview of the 2026 Future Healthcare & Pharma Top 100 Conference

China’s Medical Innovation Stands at a Critical Crossroads.

Over the past decade, breakthroughs in foundational technologies have continued to emerge, innovative drugs and medical devices have gained accelerated regulatory approval, and medical AI has flourished. However, as the industry transitions from a period of “innovation explosion” to one of “value realization,” a fundamental question has come to the fore:How Can High-Quality Assets Gain Visibility? And How Can Transactions Be Truly Completed?

This is precisely the core question that the 2026 Future Healthcare and Pharmaceuticals Top 100 Conference seeks to address.

Over the past decade, the “Top 100 Future Healthcare Companies” list, initiated by VCBeat and VB100, has become a key benchmark for value in the industry. A total of 4,464 companies have been listed, with over 100 completing initial public offerings (IPOs) and more than 190 appearing on the list for three consecutive years. This is not merely an honor roll, but a verified directory of innovative assets.

For investors, this is a project pool that can serve directly as investment targets;

For enterprises, this represents a high-profile unveiling of value that has drawn concentrated attention from capital, industry, and government.

For ecosystem partners, this is an industry map that clearly identifies the leading players in each sector.

Standing at the new starting point of the tenth year, we have upgraded the conference’s positioning to “"Showcasing, Trading, and Empowering Innovative Healthcare Assets in China"Platform. Centered on this positioning, the Top 100 Conference has undergone comprehensive upgrades in guest composition, content design, and on-site format—it is not merely a forum for discussing trends, but also a centralized showcase for innovative assets, a hub for capital matchmaking, and a marketplace for industry transactions.

The challenge in asset transactions often lies not in the lack of projects, but in the difficulty of finding the right partners and identifying suitable targets.

To facilitate the transition from “communication” to “matchmaking” between buyers and sellers, the 2026 Top 100 Conference has centered its exhibition area around “Assess Assets, Identify Projects, Negotiate Partnerships“For the three key stages, we have specially designed three major value domains:”

● Showcase of Top-Ranked Companies: Turning Honors into Collaboration Opportunities。

The core area of the main venue will feature a “Top 100 Future Healthcare and Pharmaceutical Projects Exhibition Zone,” showcasing companies and innovative products that made the annual list. This serves not only as a display of innovative achievements but also as a key window for buyers to intuitively assess technological strength and commercial potential.

● Innovative Assets Pictorial Exhibition: Making High-Quality Projects Visible to Capital。 

The investment portfolios of China’s Top 100 healthcare and medical investment institutions will be showcased on-site, with a focus on their high-quality portfolio companies. A “Resource Matching Wall” will also be set up in the exhibition area, providing clear visibility into financing needs and technical collaboration opportunities to help investors and industry players quickly identify potential partnership targets.

● 1-on-1 Negotiation Area: Facilitating In-Depth Engagement for Key Decision-Makers。

The Top 100 Conference breaks down the “you exhibit, I watch” barrier and resolves the matchmaking dilemma of “being unable to find the right contacts” by establishing an exclusive “1-on-1 Asset Negotiation Zone.” Prior to the event, demand matching is conducted to schedule dedicated discussion slots for investment institutions, industrial companies, and innovative enterprises. This enables key decision-makers to engage in in-depth conversations within private spaces, rapidly advancing interactions from initial contact to expressions of cooperation intent.

When high-quality assets come into view and key decision-makers gather around the same table, new collaborations and transactions often begin.

If the design of the exhibition area addresses the question of “where to trade,” then content curation answers the questions of “what to trade” and “with whom to trade.”

Overview of the 2026 Future Healthcare & Pharma Top 100 Conference Forum

● Trends: Where Do Chinese Assets Stand in the Global Coordinate System?

Industry leaders and think tank scholars will analyze the evolving landscape of global healthcare innovation from a worldwide perspective, exploring the positioning of Chinese assets in the new industrial cycle and the latest trends in cross-border cooperation and transaction rules. By sharing insights from the buyer’s perspective, they will provide industry participants with key reference points for understanding current changes and strategizing for the future.

● Strategy: How Can Innovative Enterprises Successfully Navigate the Path to Industrialization?

No empty talk, only real-world practice. Centered on sections such as “Innovation with Methodology” and “1-on-1 Technical Discourse,” multiple benchmark enterprises will review key decisions made during technological breakthroughs, industrial commercialization, and global expansion. From medical device innovation to biopharmaceutical R&D, and from digital health to healthcare service ecosystems, real-life cases from frontline entrepreneurs will illustrate diverse pathways for the growth of innovative assets.

● IPO Services: A Critical Step for Companies Entering the Capital Market?

If you are planning to enter the capital markets, this is an event not to be missed. Through two key segments—“Dialogue with Exchanges” and “IPO Practical Insights”—representatives from major exchanges such as the Hong Kong Stock Exchange, Shanghai Stock Exchange, and Shenzhen Stock Exchange, along with senior executives from listed companies, will share insights on changes in listing regulations, selection of listing pathways, and capital market strategies. This will help enterprises gain a clearer understanding of the critical milestones from growth to going public.

●Value Investing: Where Will the Next Round of Value Trading Take Place?

Domestic and international investment institutions gathered to jointly explore the pricing logic, investment cycles, and exit strategies for medical innovation assets through the “Investment Wisdom” and “Investment Roundtable” sessions. As industrial capital, US dollar funds, and long-term capital engage in dialogue on the same platform, new opportunities for potential collaboration and transactions will be created.

In addition to the main forum, the conference will host multiple thematic forums focusing on the most active segments in current healthcare innovation transactions, coveringBrain-Computer Interfaces, Large Medical AI Models, Ophthalmic Innovation, Innovative Drug Business Development, Global Expansion of Pharmaceuticals and Medical Devicesand other sectors.

For instance, the Brain-Computer Interface Forum will discuss key application scenarios for translating technology from the laboratory to clinical practice; the AI Large Model Forum will focus on the commercial value and asset valuation logic of medical large language models; the Innovative Drug BD Forum will analyze collaboration models and pricing trends in the current transaction environment; and the Medical Device and Pharmaceutical Globalization Forum will deconstruct the real challenges and solutions for the global expansion of Chinese assets...

From technological breakthroughs to commercialization pathways, from BD collaborations to international expansion, every forum seeks to answer the same question:Which Sector Will See the Next Medical Innovation Deal?

Here, the discussion features not only keynote speakers but also core buy-side participants, leading enterprises, and seasoned investors within the sector. They have gathered to identify the key inflection points for the next surge in value through the collision of perspectives.

From the precise alignment across the three major exhibition zones to the in-depth exploration of the four thematic sections of the main forum and the specialized tracks of the hotspot forums—every element of the design is directed toward a single goal:Reduce transaction costs, improve matching efficiency, and enable high-quality assets to find suitable partners more quickly.

In May, Shanghai: 2026 Future Healthcare & Pharma Top 100 Conference. We cordially invite every industry partner to join us in witnessing and participating in this in-depth practice focused on the “Showcasing, Trading, and Empowerment of China’s Healthcare Innovation Assets.”

Here, understand the asset landscape of China's healthcare innovation.

Here, every transaction of high-quality assets happens efficiently.